---
schema_version: "secwatch.filing_event.v1"
accession: "0001447362-24-000006"
form_type: "8-K"
ticker: "CSTL"
cik: "0001447362"
company_name: "CASTLE BIOSCIENCES INC"
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:11:05.023323+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Castle Biosciences expects 2023 revenue >$210M, exceeding guidance; test volume +59%

## Summary
- Expects 2023 total revenue >$210M, at least 53% growth over 2022, surpassing prior guidance floor of $200M.
- Delivered 70,429 total test reports in 2023, up 59% YoY; Q4 reports 20,284, up 60% YoY.
- TissueCypher Barrett's Esophagus test reports surged 328% YoY in 2023; IDgenetix up 236%.
- Year-end cash, equivalents and short-term investments expected ~$243M.
- Preliminary results, subject to audit completion; final results may differ.

## SEC filing metadata
- accession: 0001447362-24-000006
- form_type: 8-K
- ticker: CSTL
- cik: 0001447362
- company_name: CASTLE BIOSCIENCES INC
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447362/000144736224000006/0001447362-24-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447362/000144736224000006/cstl-20240107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001447362-24-000006
- JSON: https://secwatch.observer/filing/0001447362-24-000006.json
- Plain text: https://secwatch.observer/filing/0001447362-24-000006.txt

## Key facts
- Earnings Releases
  CASTLE BIOSCIENCES INC reported the fourth quarter and year ended Dec. 31, 2023 results: revenue more than $210 million.
  - Period: the fourth quarter and year ended Dec. 31, 2023
  - Revenue: more than $210 million
  - Result: preliminary results
  source text: contains --- EX-99.2 (EX-99.2) --- Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results Expect to deliver 2023 total revenue of more than $210 million, at least 53% growth over 2022 Delivered 70,429 total test reports in 2023, an increase of 59% compared to 2022 Year-end 2023 cash, cash equivalents and marketable investment
  evidence_url: https://www.sec.gov/Archives/edgar/data/1447362/000144736224000006/0001447362-24-000006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.